NIH: National Cancer Institute, US and other funders
Closing Date 2nd June 2020
Visit funder’s web page for these opportunities
The National Cancer Institute invites applications for its research answers to National Cancer Institute’s provocative questions (R01 clinical trial optional) funding opportunity. This supports research projects designed to solve specific problems and paradoxes in cancer research. These problems are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Each application must address one of the following questions:
•what the underlying causes of the unexplained rising incidence in early-onset cancers are;
•how intermittent fasting affects cancer incidence, treatment response or outcome;
•how selective pressures affect cell competition and cooperation during cancer initiation and development;
•what mechanisms explain sex differences in cancer incidence, lesion location or response to therapy;
•what strategies can block or reverse the emergence of new cell lineage states induced by cancer treatments;
•how cancer cachexia can be reversed;
•what methods can be developed to integrate patient-generated health data into electronic health records;
•what strategies improve and sustain coordination of comprehensive healthcare for underserved cancer patients with comorbidities;
•what methods can be developed to effectively study small or rare populations relevant to cancer research.
Two funding mechanisms announced
1.Research answers to National Cancer Institute’s provocative questions (R01 clinical trial optional)
This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, RFA-CA-20-005, which solicits applications under the exploratory/developmental (R21) grant mechanism.
US and foreign for-profit and non-profit organisations and public and private organisations may apply.
The total budget for fiscal year 2021 is worth USD 12 million to fund approximately 15 to 20 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed five years.
2. Research answers to National Cancer Institute’s provocative questions (R21 clinical trial optional)
This supports research projects designed to solve specific problems and paradoxes in cancer research. Grants are worth up to USD 275,000 each over two years.
Maximum award: USD 275,000
Closing date: 2nd June 2020 (recurring)